BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 32012401)

  • 1. Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma.
    Sudo S; Kajiya H; Okano S; Sasaki M; Katsumata Y; Ohno J; Ikebe T; Hiraki A; Okabe K
    Cancer Sci; 2020 Apr; 111(4):1113-1123. PubMed ID: 32012401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
    Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
    Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1.
    Chen L; Zhu Q; Lu L; Liu Y
    Bioengineered; 2020 Dec; 11(1):91-102. PubMed ID: 31906769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
    Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
    Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression.
    Wang X; Li H; Shi J
    Biomed Res Int; 2019; 2019():8645153. PubMed ID: 31275988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance.
    Su L; Wang Y; Xiao M; Lin Y; Yu L
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):484-91. PubMed ID: 20868995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
    Hirai M; Kitahara H; Kobayashi Y; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
    Int J Oncol; 2017 Jan; 50(1):41-48. PubMed ID: 27922697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of KPNA2 inhibits autophagy in oral squamous cell carcinoma cell lines by blocking p53 nuclear translocation.
    Lin F; Gao L; Su Z; Cao X; Zhan Y; Li Y; Zhang B
    Oncol Rep; 2018 Jul; 40(1):179-194. PubMed ID: 29781035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.
    Suenaga N; Kuramitsu M; Komure K; Kanemaru A; Takano K; Ozeki K; Nishimura Y; Yoshida R; Nakayama H; Shinriki S; Saito H; Jono H
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel miR-365-3p/EHF/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing β5-integrin/c-met signaling pathway.
    Huang WC; Jang TH; Tung SL; Yen TC; Chan SH; Wang LH
    J Exp Clin Cancer Res; 2019 Feb; 38(1):89. PubMed ID: 30782177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and Prognostic Analysis of PD-L1 and PD-L2 Expression in Surgically Resected Primary Tongue Squamous Cell Carcinoma.
    Furukawa K; Kawasaki G; Yoshida T; Umeda M
    Anticancer Res; 2021 Jan; 41(1):101-111. PubMed ID: 33419803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AIM2 promotes irradiation resistance, migration ability and PD-L1 expression through STAT1/NF-κB activation in oral squamous cell carcinoma.
    Chiu HW; Lee HL; Lee HH; Lu HW; Lin KY; Lin YF; Lin CH
    J Transl Med; 2024 Jan; 22(1):13. PubMed ID: 38166970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HOXA1 silencing inhibits cisplatin resistance of oral squamous cell carcinoma cells via IκB/NF-κB signaling pathway.
    Zhu R; Mao Y; Xu X; Li Y; Zheng J
    Anticancer Drugs; 2024 Jul; 35(6):492-500. PubMed ID: 38477942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
    Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
    Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis.
    Zhou X; Ren Y; Liu A; Jin R; Jiang Q; Huang Y; Kong L; Wang X; Zhang L
    Sci Rep; 2014 Dec; 4():7461. PubMed ID: 25514838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
    Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-21 inhibitor sensitizes human OSCC cells to cisplatin.
    Wang W; Songlin P; Sun Y; Zhang B; Jinhui W
    Mol Biol Rep; 2012 May; 39(5):5481-5. PubMed ID: 22249446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma Through Ras/MAPK Signaling.
    Lu M; Wang C; Chen W; Mao C; Wang J
    DNA Cell Biol; 2018 Apr; 37(4):381-388. PubMed ID: 29364705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma.
    Sasaya T; Kubo T; Murata K; Mizue Y; Sasaki K; Yanagawa J; Imagawa M; Kato H; Tsukahara T; Kanaseki T; Tamura Y; Miyazaki A; Hirohashi Y; Torigoe T
    Cancer Med; 2023 Feb; 12(4):4605-4615. PubMed ID: 36200687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Licochalcone C induced apoptosis in human oral squamous cell carcinoma cells by regulation of the JAK2/STAT3 signaling pathway.
    Oh HN; Seo JH; Lee MH; Kim C; Kim E; Yoon G; Cho SS; Cho YS; Choi HW; Shim JH; Chae JI
    J Cell Biochem; 2018 Dec; 119(12):10118-10130. PubMed ID: 30129052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.